Probleme bei der Darstellung von ARIVA.DE?

  • Laden unsere Charts bei Ihnen nicht?
  • Wird unser Forum bei Ihnen nicht korrekt dargestellt?

Sie nutzen einen Adblocker, der hierfür verantwortlich ist. Hierauf hat ARIVA.DE leider keinen Einfluss. Bitte heben Sie die Blockierung von ARIVA.DE in Ihrem Adblocker auf.

Probleme bei der Darstellung von ARIVA.DE?

Top-Thema

18:17 Uhr
AKTIEN IM FOKUS 2: Gebot für Abertis gibt Hochtief-​Papier Auftrieb

Omnicell Reports Results for Fiscal Year and Fourth Quarter 2016

Mittwoch, 15.02.2017 22:05 von

PR Newswire

MOUNTAIN VIEW, Calif., Feb. 15, 2017 /PRNewswire/ -- Omnicell, Inc. (NASDAQ: OMCL), a leading provider of medication and supply management solutions to healthcare systems, today announced results for its fiscal year and fourth quarter ended December 31, 2016. 

GAAP results: Revenue for the fourth quarter of 2016 was $172.0 million, down $4.8 million or 2.7% from the third quarter of 2016, and up $41.7 million or 32.0% from the fourth quarter of 2015. Revenue for the year ended December 31, 2016 was $692.6 million, up $208.1 million or 42.9% from the year ended December 31, 2015.

Fourth quarter 2016 net income as reported in accordance with U.S. generally accepted accounting principles (GAAP) was $0.2 million, or $0.00 per diluted share. This compares to GAAP net income of $2.0 million, or $0.05 per diluted share, for the third quarter of 2016, and GAAP net income of $7.7 million, or $0.21 per diluted share, for the fourth quarter of 2015.

GAAP net income for the year ended December 31, 2016 was $0.6 million, or $0.02 per diluted share. GAAP net income was $30.8 million, or $0.84 per diluted share, for the year ended December 31, 2015, which includes a $3.4 million gain on business combination of an equity investment.

Non-GAAP results: Non-GAAP revenue for the fourth quarter of 2016 was $174.6 million, down $4.8 million, or 2.7% from the third quarter of 2016, and up $44.3 million or 34.0% from the fourth quarter of 2015. Non-GAAP revenue for the twelve months ended December 31, 2016 was $703.3 million, up $218.7 million, or 45.1% from December 31, 2015.

Non-GAAP net income for the fourth quarter of 2016 was $13.8 million, or $0.37 per diluted share. This compares to non-GAAP net income of $14.9 million, or $0.40 per diluted share, for the third quarter of 2016 and $14.4 million, or $0.40 per diluted share, for the fourth quarter of 2015. 

Non-GAAP net income for the year ended December 31, 2016 was $55.7 million, or $1.51 per diluted share. This compares to non-GAAP net income of $48.7 million, or $1.33 per diluted share for the year ended December 31, 2015. Non-GAAP net income for each period presented excludes, when applicable, the effect of stock-based compensation expense, amortization expense for all intangible assets associated with past acquisitions, acquisition expenses, fair value adjustments related to business acquisition, amortization of debt issuance cost, and gain on business combination of an equity investment in Avantec.

Total bookings for the year ended December 31, 2016 were $541 million compared to total bookings for the year ended December 31, 2015 of $392 million.

"2016 was a successful year for Omnicell with record bookings, revenues and earnings," said Randall Lipps, Omnicell president, CEO and chairman. "We are proud of the company's financial performance and our strategic execution aimed at supporting health systems in achieving their patient safety, operational and financial goals.''

"Our customers tell us medication management is central to their patient safety and operational strategies. Our recent wins showcase the strength of our comprehensive and innovative solutions that enable us to be a vital partner. The company is well positioned to take advantage of the great opportunities ahead in 2017,'' Mr. Lipps added.

2017 Guidance:

The fiscal year 2017 financial results are expected to be characterized by two distinct phases, as revenue and profitability are expected to be impacted by the Company's XT Series product introduction transition and manufacturing ramp up:

A. The first phase encompasses the introduction and ramp up of manufacturing for the XT Series in the first quarter of 2017, with anticipated dynamics including:

  • Conversion of G4 product bookings and backlog, and sales quotes to XT Series bookings;
  • XT Series manufacturing volume ramp up;
  • Installation of the XT Series product at launch customers;
  • XT Series manufacturing ramp up cost;
  • Reduction of workforce by approximately 100 positions, and the closure of the Company's Tennessee office; and
  • General hiring delays

For the first quarter of 2017, the Company expects non-GAAP revenue to be between $150 million and $155 million. Omnicell expects first quarter of 2017 non-GAAP earnings to be between $0.00 and $0.04 per share.

B. The second phase encompasses the acceleration of installations and conversion of product backlog into revenue during the second through the fourth quarters of 2017, with anticipated dynamics including:

  • Launch of Acudose-Rx® on XT Series;
  • Improvement of XT Series production cost;
  • Above 20% growth rate for product bookings;
  • Return to 8%-12% revenue organic growth range rate;
  • XT Series cost of sales reductions as revenue ramps up;
  • Continuation of cost reduction initiatives; and
  • Implement development and manufacturing Centers of Excellence (''COEs")

As part of the next phase of the integration of the acquisition of Aesynt the Company is creating the following Centers of Excellence ("COEs") for product development, engineering, and manufacturing:

  • the Point of Use COE in California;
  • the Robotics and Central Pharmacy COE in Pittsburgh, Pennsylvania; and
  • the Medication Adherence Consumables COE in St. Petersburg, Florida

The Company today announced a reduction of its workforce by approximately 100 full-time employees, or about 4% of its total headcount, anticipated to be completed in the first quarter of 2017. This reduction in force includes the closure of the Company's Nashville, Tennessee office, anticipated in the first quarter of 2017, and the closure of the Company's manufacturing facility in Slovenia, anticipated in the third quarter of 2017. The Company expects to incur approximately $4 million of restructuring expenses in connection with the reduction in force for one-time termination benefits, comprised principally of severance. The Company expects to incur approximately an additional $4 million of restructuring expenses in connection with facility leases, dilapidation, and other one-time facilities-related expenses.

For the second through the fourth quarters of 2017, the Company expects non-GAAP revenue to be between $590 million and $605 million, representing 8%-12% growth both on a reported and organic basis. For the second through fourth quarters of 2017, the Company expects non-GAAP earnings to be between $1.32 and $1.38 per share, representing above 15% growth, both on a reported and organic basis.

For the year 2017, Omnicell expects product bookings to be between $570 million and $590 million. The Company expects non-GAAP revenue to be between $740 million and $760 million, and non-GAAP earnings to be between $1.32 and $1.42 per share.

The table below summarizes Omnicell's 2017 guidance for the two distinct phases outlined above:


Q1'17

Q2'17 through Q4'17

Total Year 2017

Product Bookings

<0% year over year growth

>20% year over year growth

$570 million - $590 million

Non-GAAP Revenue

$150 million - $155 million

$590 million - $605 million

$740 million - $760 million

Non-GAAP EPS

$0.00 - $0.04

$1.32 - $1.38

$1.32 - $1.42

 

Reporting Segments

The Company's Chief Operating Decision Maker (''CODM") is its Chief Executive Officer. The CODM allocates resources and evaluates the performance of the Company's segments using information about its revenues, gross profit, and income from operations. Such evaluation excludes general corporate-level costs that are not specific to either of the reportable segments and are managed separately at the corporate level. Corporate-level costs include expenses related to executive management, finance and accounting, human resources, legal, training and development, and certain administrative expenses. The operating results of the acquired Aesynt business acquired in the first quarter of 2016 are included in the Company's Automation and Analytics reportable segment. The operating results of the Ateb business acquired in the fourth quarter of 2016 are included in the Company's Medication Adherence reportable segment.

Omnicell Conference Call Information

Omnicell will hold a conference call today, Wednesday, February 15, 2017 at 1:30 p.m. PT to discuss fourth quarter financial results. The conference call can be monitored by dialing 1-800-696-5518 within the U.S. or 1-706-758-4883 for all other locations. The Conference ID # is 36561632. Internet users can access the conference call at http://ir.omnicell.com/events.cfm. A replay of the call will be available today at approximately 4:30 p.m. PT and will be available until 11:59 p.m. PT on March 29, 2017. The replay access numbers are 1-855-859-2056 within the U.S. and 1-404-537-3406 for all other locations, Conference ID # is 36561632.

About Omnicell

Since 1992, Omnicell (NASDAQ: OMCL) has been inspired to create safer and more efficient ways to manage medications and supplies across all care settings. As a leader in medication and supply dispensing automation, central pharmacy automation, IV robotics, analytics software, and medication adherence and packaging systems, Omnicell is focused on improving care across the entire healthcare continuum-from the acute care hospital setting, to post-acute skilled nursing and long-term care facilities, to the patient's home.

Over 4,000 customers worldwide use Omnicell® automation and analytics solutions to increase operational efficiency, reduce medication errors, deliver actionable intelligence and improve patient safety.

Omnicell's innovative medication adherence solutions, used by over 32,000 institutional and retail pharmacies in North America and the United Kingdom, are designed to improve patient adherence to prescriptions, helping to reduce costly hospital readmissions.

Recent Omnicell acquisitions, including Ateb, add distinct capabilities, particularly in central pharmacy, IV robotics, and pharmacy software, creating the broadest medication management product portfolio in the industry.

For more information about Omnicell, Inc. please visit www.omnicell.com.

Forward-Looking Statements

To the extent any statements contained in this release deal with information that is not historical, these statements are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. As such, they are subject to the occurrence of many events outside Omnicell's control and are subject to various risk factors that could cause actual results to differ materially from those expressed or implied in any forward-looking statement. Such statements include, but are not limited to Omnicell's momentum, pipeline and new sales opportunities, bookings, profit and revenue growth, and the success of Omnicell's strategy for growth, including differentiated products, expansion into new markets and targeted acquisitions. Risks that contribute to the uncertain nature of the forward-looking statements include our ability to take advantage of the growth opportunities in medication management across the spectrum of healthcare settings from long term care to home care, our ability to successfully convert product backlog and sales quotes to our XT Series, our ability to execute the manufacturing ramp up of XT Series, impact of the reduction in our workforce and closure of our Nashville and Slovenia facilities, our ability to continue cost reduction efforts, and our ability to implement development and manufacturing Centers of Excellence, unfavorable general economic and market conditions, risks to growth and acceptance of our products and services, including competitive conversions, and to growth of the clinical automation and workflow automation market generally, the potential of increasing competition, potential regulatory changes, the ability of the company to improve sales productivity to grow product bookings, to develop new products and to acquire and successfully integrate companies. These and other risks and uncertainties are described more fully in Omnicell's most recent filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on forward-looking statements. All forward-looking statements contained in this press release speak only as of the date on which they were made. Omnicell undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Use of Non-GAAP Financial Information

This press release contains financial measures that are not calculated in accordance with U.S. generally accepted accounting principles (GAAP). Our management evaluates and makes operating decisions using various performance measures. In addition to Omnicell's GAAP results, we also consider non-GAAP revenue, non-GAAP gross profit, non-GAAP operating expenses, non-GAAP net income, and non-GAAP net income per diluted share. Additionally, we calculate Adjusted EBITDA (another non-GAAP measure) by means of adjustments to GAAP Net Income. These non-GAAP results should not be considered as an alternative to gross profit, operating expenses, net income, net income per diluted share, or any other performance measure derived in accordance with GAAP. We present these non-GAAP results because we consider them to be important supplemental measures of Omnicell's performance.

Our non-GAAP revenue, non-GAAP gross profit, non-GAAP operating expenses, non-GAAP net income and non-GAAP net income per diluted share are exclusive of certain items to facilitate management's review of the comparability of Omnicell's core operating results on a period to period basis because such items are not related to Omnicell's ongoing core operating results as viewed by management. We define our "core operating results" as those revenues recorded in a particular period and the expenses incurred within that period that directly drive operating income in that period. Management uses these non-GAAP financial measures in making operating decisions because, in addition to meaningful supplemental information regarding operating performance, the measures give us a better understanding of how we should invest in research and development, fund infrastructure growth and evaluate the effectiveness of marketing strategies. In calculating the above non-GAAP results, management specifically adjusted for the following excluded items:

a) Stock-based compensation expense. We excluded from our non-GAAP results the expense related to equity-based compensation plans as they represent expenses that do not require cash settlement from Omnicell.

b) Intangible assets amortization from business acquisitions. We excluded from our non-GAAP results the intangible assets amortization expense resulting from our past acquisitions. These non-cash charges are not considered by management to reflect the core cash-generating performance of the business and therefore are excluded from our non-GAAP results.

c) Amortization of debt issuance cost. Debt issuance cost represents costs associated with the issuance of Term Loan and Revolving Line of Credit facilities. The cost includes underwriting fees, original issue discount, ticking fee, and legal fees. This non-cash expense is not considered by management to reflect the core cash-generating performance of the business and therefore is excluded from our non-GAAP results.

d) Acquisition accounting impact related to deferred revenue. In connection with acquisition of Aesynt, business combination rules require us to account for the fair values of arrangements for which acceptance has not been obtained, and post installation support has not been provided in our purchase accounting. The non-GAAP adjustment to our revenues is intended to include the full amounts of such revenues. We believe the adjustment to these revenues is useful as a measure of the ongoing performance of our business.

e) Inventory fair value adjustments. In connection with acquisition of Aesynt, business combination rules require us to account for the fair values of inventory acquired in our purchase accounting. The non-GAAP adjustment to the cost of revenues is intended to include the impact of such adjustment. We believe the adjustment is useful as a measure of the ongoing performance of our business.

f) Acquisition related expenses. We excluded from the non-GAAP results the expenses which are related to the recent acquisitions. These expenses are unrelated to our ongoing operations and we do not expect them to occur in the ordinary course of business. We believe that excluding these acquisition related expenses provides more meaningful comparisons of the financial results to our historical operations and forward looking guidance and the financial results of less acquisitive peer companies.

g) Gain on business combination of an equity investment. We excluded from our non-GAAP results the gain on a minority equity investment in a private company, Avantec, which was recognized in relation to the acquisition by Omnicell of the remainder of the company. This non-cash gain is not considered by management to reflect the core cash-generating performance of the business and therefore is excluded from our non-GAAP results.

Management adjusts for the above items because management believes that, in general, these items possess one or more of the following characteristics: their magnitude and timing is largely outside of Omnicell's control; they are unrelated to the ongoing operation of the business in the ordinary course; they are unusual and we do not expect them to occur in the ordinary course of business; or they are non-operational, or non-cash expenses involving stock compensation plans.

We believe that the presentation of these non-GAAP financial measures is warranted for several reasons:

1) Such non-GAAP financial measures provide an additional analytical tool for understanding Omnicell's financial performance by excluding the impact of items which may obscure trends in the core operating results of the business;

2) Since we have historically reported non-GAAP results to the investment community, we believe the inclusion of non-GAAP numbers provides consistency and enhances investors' ability to compare our performance across financial reporting periods;

3) These non-GAAP financial measures are employed by Omnicell's management in its own evaluation of performance and are utilized in financial and operational decision making processes, such as budget planning and forecasting; and

4) These non-GAAP financial measures facilitate comparisons to the operating results of other companies in our industry, which use similar financial measures to supplement their GAAP results, thus enhancing the perspective of investors who wish to utilize such comparisons in their analysis of our performance.

Set forth below are additional reasons why share-based compensation expense is excluded from our non-GAAP financial measures:

i) While share-based compensation calculated in accordance with ASC 718 constitutes an ongoing and recurring expense of Omnicell, it is not an expense that requires cash settlement by Omnicell. We therefore exclude these charges for purposes of evaluating core operating results. Thus, our non-GAAP measurements are presented exclusive of stock-based compensation expense to assist management and investors in evaluating our core operating results.

ii) We present ASC 718 share-based payment compensation expense in our reconciliation of non-GAAP financial measures on a pre-tax basis because the exact tax differences related to the timing and deductibility of share-based compensation, under ASC 718 are dependent upon the trading price of Omnicell's common stock and the timing and exercise by employees of their stock options. As a result of these timing and market uncertainties the tax effect related to share-based compensation expense would be inconsistent in amount and frequency and is therefore excluded from our non-GAAP results.

Our Adjusted EBITDA calculation is defined as earnings before interest income and expense, taxes, depreciation and amortization, and non-cash expenses, including ASC 718 stock compensation expense, as well as certain non-GAAP adjustments.

As stated above, we present non-GAAP financial measures because we consider them to be important supplemental measures of performance. However, non-GAAP financial measures have limitations as an analytical tool and should not be considered in isolation or as a substitute for Omnicell's GAAP results. In the future, we expect to incur expenses similar to certain of the non-GAAP adjustments described above and expect to continue reporting non-GAAP financial measures excluding such items. Some of the limitations in relying on non-GAAP financial measures are:

· Omnicell's stock option and stock purchase plans are important components of incentive compensation arrangements and will be reflected as expenses in Omnicell's GAAP results for the foreseeable future under ASC 718.

· Other companies, including companies in Omnicell's industry, may calculate non-GAAP financial measures differently than Omnicell, limiting their usefulness as a comparative measure.

Pursuant to the requirements of SEC Regulation G, a detailed reconciliation between Omnicell's non-GAAP and GAAP financial results is set forth in the financial tables at the end of this press release. Investors are advised to carefully review and consider this information strictly as a supplement to the GAAP results that are contained in this press release and in Omnicell's SEC filings.

 

Omnicell, Inc.

Condensed Consolidated Statements of Operations

(Unaudited, in thousands, except per share data)



Three Months Ended


Years Ended


December 31,
 2016


September 30,
 2016


December 31,
 2015


December 31,
 2016


December 31,
 2015

Revenues:










Product

$

125,753



$

133,621



$

104,193



$

517,944



$

388,397


Services and other revenues

46,221



43,116



26,123



174,679



96,162


  Total revenues

171,974



176,737



130,316



692,623



484,559


Cost of revenues:










Cost of product revenues

78,024



76,188



55,099



302,437



198,418


Cost of services and other revenues

19,621



19,041



10,137



76,386



38,211


  Total cost of revenues

97,645



95,229



65,236



378,823



236,629


Gross profit

74,329



81,508



65,080



313,800



247,930


Operating expenses:










Research and development

14,902



15,264



9,219



57,799



35,160


Selling, general and administrative

59,608



61,316



43,891



249,520



167,581


Gain on business combination









(3,443)


  Total operating expenses

74,510



76,580



53,110



307,319



199,298


Income (loss) from operations

(181)



4,928



11,970



6,481



48,632


Interest and other income (expense), net

(1,656)



(2,721)



(753)



(8,429)



(2,388)


Income (loss) before provision for income taxes

(1,837)



2,207



11,217



(1,948)



46,244


Provision (benefit) for income taxes

(1,994)



224



3,562



(2,551)



15,484


Net income

$

157



$

1,983



$

7,655



$

603



$

30,760


Net income per share:










Basic

$



$

0.05



$

0.22



$

0.02



$

0.86


Diluted

$



$

0.05



$

0.21



$

0.02



$

0.84


Weighted average shares outstanding:










Basic

36,553



36,332



35,482



36,156



35,857


Diluted

37,256



37,079



36,172



36,864



36,718


 

Omnicell, Inc.

Condensed Consolidated Balance Sheets

(Unaudited, in thousands)



December 31,
2016


December 31,
2015





ASSETS

Current assets:




Cash and cash equivalents

$

54,488



$

82,217


Accounts receivable, net

150,303



107,957


Inventories

69,297



46,594


Prepaid expenses

28,646



19,586


Other current assets

12,674



7,774


Total current assets

315,408



264,128


Property and equipment, net

42,011



32,309


Long-term investment in sales-type leases, net

20,585



14,484


Goodwill

327,724



147,906


Intangible assets, net

190,283



89,665


Long-term deferred tax assets

4,041



2,361


Other long-term assets

35,051



27,894


Total assets

$

935,103



$

578,747






LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:




Accounts payable

$

27,069



$

22,646


Accrued compensation

26,722



18,195


Accrued liabilities

31,195



30,133


Long-term debt, current portion, net

8,410




Deferred revenue, net

87,516



53,656


Total current liabilities

180,912



124,630


Long-term, deferred revenue

17,051



17,975


Long-term deferred tax liabilities

51,592



21,822


Other long-term liabilities

8,210



11,932


Long-term debt, net

245,731




Total liabilities

503,496



176,359


Stockholders' equity:




Total stockholders' equity

431,607



402,388


Total liabilities and stockholders' equity

$

935,103



$

578,747


 

Omnicell, Inc.

Condensed Consolidated Statements of Cash Flows

(Unaudited, in thousands)



Years Ended


2016


2015

Operating Activities




Net income

$

603



$

30,760


Adjustments to reconcile net income to net cash provided by operating activities:




Depreciation and amortization

58,362



25,639


Loss on disposal of fixed assets

35



238


Gain on business combination



(3,443)


Gain related to contingent liability

(600)




Share-based compensation expense

19,500



14,921


Income tax benefits from employee stock plans

1,702



4,535


Excess tax benefits from employee stock plans

(1,963)



(4,724)


Deferred income taxes

(10,882)



(1,092)


Amortization of debt financing fees

1,590




Changes in operating assets and liabilities:




 Accounts receivable

8,047



(17,941)


 Inventories

(3,362)



(10,032)


 Prepaid expenses

(4,321)



4,049


 Other current assets

(1,093)



638


 Investment in sales-type leases

(9,639)



(4,661)


 Other long-term assets

2,043



496


 Accounts payable

(4,963)



(2,841)


 Accrued compensation

(2,052)



(2,032)


 Accrued liabilities

(3,287)



5,456


 Deferred revenue

4,480



(5,521)


 Other long-term liabilities

(6,263)



(683)


Net cash provided by operating activities

47,937



33,762


Investing Activities




Purchase of intangible assets, intellectual property and patents

(1,372)



(415)


Software development for external use

(14,348)



(12,132)


Purchases of property and equipment

(13,445)



(7,542)


Business acquisitions, net of cash acquired

(312,158)



(25,507)


Net cash used in investing activities

(341,323)



(45,596)


Financing Activities




Proceeds from debt, net

287,051




Repayment of debt and revolving credit facility

(34,500)




Payment for contingent consideration

(3,000)




Proceeds from issuances under stock-based compensation plans

17,691



17,091


Employees' taxes paid related to restricted stock units

(3,490)



(3,627)


Excess tax benefits from employee stock plans

1,963



4,724


Common stock repurchases



(50,021)


Net cash provided by (used in) financing activities

265,715



(31,833)


Effect of exchange rate changes on cash and cash equivalents

(58)



(4)


Net decrease in cash and cash equivalents

(27,729)



(43,671)


Cash and cash equivalents at beginning of period

82,217



125,888


Cash and cash equivalents at end of period

$

54,488



$

82,217


 

Omnicell, Inc.

Reconciliation of GAAP to Non-GAAP

(Unaudited, in thousands, except per share data and percentages)



Three Months Ended


Twelve Months Ended


December 31,
2016


September 30,
2016


December 31,
2015


December 31,
2016


December 31,
2015











Reconciliation of GAAP revenue to non-GAAP revenue:



GAAP revenue

$

171,974



$

176,737



$

130,316



$

692,623



$

484,559



Acquisition accounting impact related to deferred revenue

2,663



2,663





10,652




Non-GAAP revenue

$

174,637



$

179,400



$

130,316



$

703,275



$

484,559













Reconciliation of GAAP gross profit to non-GAAP gross profit:



GAAP gross profit

$

74,329



$

81,508



$

65,080



$

313,800



$

247,930


GAAP gross margin

43.2%



46.1%



49.9%



45.3%



51.2%



Share-based compensation expense

776



628



481



2,596



2,111



Amortization of acquired intangibles

5,266



5,199



547



20,890



2,016



Acquisition accounting impact related to deferred revenue

2,663



2,663





10,652





Inventory fair value adjustments

921



920





3,682





Acquisition related expenses

5



44





277




Non-GAAP gross profit

$

83,960



$

90,962



$

66,108



$

351,897



$

252,057


Non-GAAP gross margin

48.1%



50.7%



50.7%



50.0%



52.0%













Reconciliation of GAAP operating expenses to non-GAAP operating expenses:

GAAP operating expenses

$

74,510



$

76,580



$

53,110



$

307,319



$

199,298


GAAP operating expenses % to total revenue

43.3%



43.3%



40.8%



44.4%



41.1%



Share-based compensation expense

(4,663)



(4,049)



(3,173)



(16,904)



(12,810)



Amortization of acquired intangibles

(3,752)



(3,714)



(1,354)



(15,251)



(4,904)



Acquisition related expenses

(829)



(342)



(2,898)



(5,753)



(2,898)



Gain on business combination









3,443


Non-GAAP operating expenses

$

65,266



$

68,475



$

45,685



$

269,411



$

182,129


Non-GAAP operating expenses % to total revenue

37.4%



38.2%



35.1%



38.3%



37.6%











Three Months Ended


Twelve Months Ended


December 31,
2016


September 30,
2016


December 31,
2015


December 31,

 2016


December 31,
2015

Reconciliation of GAAP income (loss) from operations to non-GAAP income from operations:

GAAP income (loss) from operations

$

(181)



$

4,928



$

11,970



$

6,481



$

48,632


GAAP operating income % to total revenue

(0.1)%



2.8%



9.2%



0.9%



10.0%



Share-based compensation expense

5,438



4,677



3,654



19,500



14,921



Amortization of acquired intangibles

9,017



8,913



1,901



36,141



6,920



Acquisition accounting impact related to deferred revenue

2,663



2,663





10,652





Inventory fair value adjustments

921



920





3,682





Acquisition related expenses

834



386



2,898



6,029



2,898



Gain on business combination









(3,443)


Non-GAAP income from operations

$

18,692



$

22,487



$

20,423



$

82,485



$

69,928


Non-GAAP operating income % to total Non-GAAP revenue

10.7%



12.5%



15.7%



11.7%



14.4%













Reconciliation of GAAP net income to non-GAAP net income:


GAAP net income

$

157



$

1,983



$

7,655



$

603



$

30,760



Share-based compensation expense

5,438



4,677



3,654



19,500



14,921



Amortization of acquired intangibles

9,017



8,913



1,901



36,141



6,920



Acquisition accounting impact related to deferred revenue

2,663



2,663





10,652





Inventory fair value adjustments

921



920





3,682





Acquisition related expenses

632



783



2,898



7,019



2,898



Gain on business combination









(3,443)



Tax effect of the adjustments above(a)

(5,031)



(5,047)



(1,665)



(21,850)



(3,368)


Non-GAAP net income

$

13,797



$

14,892



$

14,443



$

55,747



$

48,688



Reconciliation of GAAP net income per share - diluted to non-GAAP net income per share - diluted:




Shares - diluted GAAP

37,256



37,079



36,172



36,864



36,718













Shares - diluted Non-GAAP

37,256



37,079



36,172



36,864



36,718













GAAP net income per share - diluted

$



$

0.05



$

0.21



$

0.02



$

0.84



Share-based compensation expense

0.15



0.13



0.10



0.53



0.41



Amortization of acquired intangibles

0.24



0.24



0.05



0.98



0.18



Acquisition accounting impact related to deferred revenue

0.07



0.07





0.29





Inventory fair value adjustments

0.02



0.02





0.10





Acquisition related expenses

0.02



0.02



0.08



0.19



0.08



Gain on business combination









(0.09)



Tax effect of the adjustments above(a)

(0.13)



(0.13)



(0.04)



(0.60)



(0.09)


Non-GAAP net income per share - diluted

$

0.37



$

0.40



$

0.40



$

1.51



$

1.33













Reconciliation of GAAP net income to non-GAAP Adjusted EBITDA:


GAAP net income

$

157



$

1,983



$

7,655



$

603



$

30,760



Share-based compensation expense

5,438



4,677



3,654



19,500



14,921



Interest (income) and expense, net

998



1,523



89



5,616



410



Depreciation and amortization expense

14,457



14,702



7,182



58,362



25,639



Acquisition accounting impact related to deferred revenue

2,663



2,663





10,652





Inventory fair value adjustments

921



920





3,682





Acquisition related expenses

632



783



2,898



7,019



2,898



Gain on business combination









(3,443)



Income tax expense (benefit)

(1,994)



224



3,562



(2,551)



15,484


Non-GAAP Adjusted EBITDA (b)

$

23,272



$

27,475



$

25,040



$

102,883



$

86,669











(a)   Tax effects calculated for all adjustments except share-based compensation expense, using the tax rate of 38%.

(b)   Defined as earnings before interest income and expense, taxes, depreciation and amortization, share-based compensation expense, as well as excluding certain non-GAAP adjustments.

 

Omnicell, Inc.

Segmented Information

(Unaudited, in thousands, except for percentages)



Three Months Ended December 31, 2016


Three Months Ended December 31, 2015


Automation
and
Analytics


Medication
Adherence


Total


Automation
and

Analytics


Medication

Adherence


Total





Revenues

$

143,583



$

28,391



$

171,974



$

105,874



$

24,442



$

130,316


Cost of revenues

77,566



20,079



97,645



48,020



17,216



65,236


Gross profit

66,017



8,312



74,329



57,854



7,226



65,080


Gross margin %

46.0%



29.3%



43.2%



54.6%



29.6%



49.9%














Operating expenses

47,402



7,325



54,727



28,889



5,937



34,826


Income from segment operations

$

18,615



$

987



$

19,602



$

28,965



$

1,289



$

30,254


Operating margin %

13.0%



3.5%



11.4%



27.4%



5.3%



23.2%














Corporate costs





19,783







18,284


   Income (loss) from operations





$

(181)







$

11,970




Omnicell, Inc.

Segmented Information

(Unaudited, in thousands, except for percentages)



Year Ended December 31, 2016


Year Ended December 31, 2015


Automation
and
Analytics


Medication
Adherence


Total


Automation
and

Analytics


Medication

Adherence


Total





Revenues

$

593,626



$

98,997



$

692,623



$

390,321



$

94,238



$

484,559


Cost of revenues

310,967



67,856



378,823



171,943



64,686



236,629


Gross profit

282,659



31,141



313,800



218,378



29,552



247,930


Gross margin %

47.6%



31.5%



45.3%



55.9%



31.4%



51.2%














Operating expenses

198,511



24,843



223,354



114,084



24,258



138,342


Income from segment operations

$

84,148



$

6,298



$

90,446



$

104,294



$

5,294



$

109,588


Operating margin %

14.2%



6.4%



13.1%



26.7%



5.6%



22.6%














Corporate costs





83,965







60,956


   Income from operations





$

6,481







$

48,632


 

Omnicell, Inc.

Segment Information Non-GAAP Gross Margin and Non-GAAP Operating Margin

(Unaudited, in thousands, except for percentages)



Three Months Ended December 31, 2016


Automation and
Analytics


Medication
Adherence


Total


Amount


% of
GAAP
Revenue


% of
Non-
GAAP Revenue


Amount


% of
GAAP
Revenue


% of
Non-
GAAP Revenue


Amount


% of
GAAP
Revenue


% of
Non-
GAAP
Revenue

Revenues

$

143,583







$

28,391







$

171,974






Acquisition accounting impact related to deferred revenue

2,663



1.9

%


1.8

%




%


%


2,663



1.5

%


1.5

%

Non-GAAP Revenues

$

146,246







$

28,391







$

174,637
























GAAP Gross profit

$

66,017



46.0

%


45.1

%


$

8,312



29.3

%


29.3

%


$

74,329



43.2

%


42.6

%

Stock-based compensation expense

668



0.5

%


0.5

%


108



0.4

%


0.4

%


776



0.5

%


0.4

%

Amortization expense of acquired intangible assets

4,820



3.4

%


3.3

%


446



1.6

%


1.6

%


5,266



3.1

%


3.0

%

Acquisition accounting impact related to deferred revenue

2,663



1.9

%


1.8

%




%


%


2,663



1.5

%


1.5

%

Inventory fair value adjustments

921



0.6

%


0.6

%




%


%


921



0.5

%


0.5

%

Acquisitions related expenses

5



%


%




%


%


5



%


%

Non-GAAP Gross profit

$

75,094



52.3

%


51.3

%


$

8,866



31.2

%


31.2

%


$

83,960



48.8

%


48.1

%



















GAAP Operating income

$

18,615



13.0

%


12.7

%


$

988



3.5

%


3.5

%


$

19,603



11.4

%


11.2

%

Stock-based compensation expense

2,672



1.9

%


1.8

%


270



0.95

%


1.0

%


2,942



1.7

%


1.7

%

Amortization expense of acquired intangible assets

7,494



5.2

%


5.1

%


1,523



5.4

%


5.4

%


9,017



5.2

%


5.2

%

Acquisition accounting impact related to deferred revenue

2,663



1.9

%


1.8

%




%


%


2,663



1.5

%


1.5

%

Inventory fair value adjustments

921



0.6

%


0.6

%




%


%


921



0.5

%


0.5

%

Acquisitions related expenses

23



%


%




%


%


23



%


%

Non-GAAP Operating income

$

32,388



22.6

%


22.1

%


$

2,781



9.8

%


9.8

%


$

35,169



20.5

%


20.1

%



















GAAP Corporate costs













$

19,784



11.5

%


11.3

%

Less: Stock-based compensation expense













2,496



1.5

%


1.4

%

Less: Acquisition-related expenses













811



0.5

%


0.5

%

Non-GAAP Corporate costs













$

16,477



9.6

%


9.4

%



















Non-GAAP Income from operations













$

18,692



10.9

%


10.7

%

 


Three Months Ended December 31, 2015


Automation and
Analytics


Medication
Adherence


Total


Amount


% of
GAAP
Revenue*


Amount


% of
GAAP
Revenue*


Amount


% of
GAAP
Revenue*

Revenues

$

105,874





$

24,442





$

130,316
















GAAP Gross profit

57,854



54.6

%


7,226



29.6

%


65,080



49.9

%

Stock-based compensation expense

411



0.4

%


70



0.3

%


481



0.4

%

Amortization expense of acquired intangible assets

214



0.2

%


333



1.4

%


547



0.4

%

Non-GAAP Gross profit

$

58,479



55.2

%


$

7,629



31.2

%


$

66,108



50.7

%













GAAP Operating income

$

28,965



27.4

%


$

1,289



5.3

%


$

30,254



23.2

%

Stock-based compensation expense

1,472



1.3

%


196



0.8

%


1,668



1.3

%

Amortization expense of acquired intangible assets

828



0.8

%


1,072



4.4

%


1,900



1.5

%













Non-GAAP Operating income

$

31,265



29.5

%


$

2,557



10.5

%


$

33,822



26.0

%













GAAP Corporate costs









$

18,284



14.0

%

Less: Stock-based compensation expense









1,986



1.5

%

Less: Acquisition related expenses









2,898



2.2

%

Non-GAAP Corporate costs









$

13,400



10.3

%













Non-GAAP Income from operations









$

20,422



15.7

%


* For the three months ended December 31, 2015, there were no differences between GAAP and non-GAAP revenues.

 

OMCL-E

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/omnicell-reports-results-for-fiscal-year-and-fourth-quarter-2016-300408221.html

SOURCE Omnicell, Inc.